Skip to main content
SpringerLink
Log in

Somatostatin Receptor Targeted-Radio-Ablation of Tumors

  • Chapter
Somatostatin

Part of the book series: Endocrine Updates ((ENDO,volume 24))

Conclusion

This chapter shows that radionuclide therapy with radiolabeled SST analogs, like [DOTA, TYR3]octreotide and [DOTA, TYR3]octreotide is a most promising new treatment modality for patients bearing sst2-positive tumors. In PRRT the goal is to deliver an effective radiation dose to the tumor without causing undesired effects in healthy tissues. Improvements in the success of radionuclide therapy also depend on the optimization of radiation doses to tumor versus normal organs in individual patients. This requires patient-specific measurements and application of models to estimate the radiation dose. It is important to collect these essential data and to perform the analyses required to optimize the treatment approaches in order to ensure the best medical care for patients. In order to improve upon current results, combined modalities such as PRRT plus surgery are of interest. The use of radiolabeled peptides may be considered in an adjuvant setting to eradicate occult metastases, possibly originating from tumor spill, after surgery of receptor-positive tumors. Starting therapy at this early stage is favourable because of the small tumor burden. PRRT can, however, also be applied for cancer recurrence at a later stage. In patients with non-resectable tumor(s), PRRT can be applied as a first step to reduce tumor size or number, followed by surgery when possible. In conclusion, radiolabeled peptides have started a new era in nuclear oncology, not only for diagnosis but also for radionuclide therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kvols, L. K., Moertel, C. G., O’Connell, M. J., Schutt, A. J., Rubin, J., and Hahn, R.G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med, 315: 663–666, 1986.

    CAS  PubMed  Google Scholar 

  2. Eriksson, B. and Oberg, K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol, 10: S31–38, 1999.

    Article  PubMed  Google Scholar 

  3. Lamberts, S. W., Krenning, E.P., and Reubi, J. C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev, 12: 450–482, 1991.

    CAS  PubMed  Google Scholar 

  4. Lamberts, S. W., Reubi, J.C., and Krenning, E. P. Somatostatin analogs in the treatment of acromegaly. Endocrinol Metab Clin North Am, 21: 737–752, 1992.

    CAS  PubMed  Google Scholar 

  5. Patel, Y. C, Greenwood, M. T., Panetta, R., Demchyshyn, L., Niznik, H., and Srikant, C. B. The somatostatin receptor family. Life Sci, 57: 1249–1265, 1995.

    Article  CAS  PubMed  Google Scholar 

  6. Patel, Y. C. Somatostatin and its receptor family. Front Neuroendocrinol, 20: 157–198, 1999.

    CAS  PubMed  Google Scholar 

  7. Schonbrunn, A. Somatostatin receptors present knowledge and future directions. Ann Oncol, 10: S17–21, 1999.

    Article  PubMed  Google Scholar 

  8. Krenning, E. P., Kwekkeboom, D. J., Oei, H. Y., de Jong, R. J., Dop, F. J., de Herder, W. W., Reubi, J. C., and Lamberts, S. W. Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing’s syndrome. Digestion, 55: 54–59, 1994.

    PubMed  Google Scholar 

  9. Krenning, E. P., Kwekkeboom, D. J., Oei, H. Y., de Jong, R. J., Dop, F. J., Reubi, J. C., and Lamberts, S. W. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci, 733: 416–424, 1994.

    CAS  PubMed  Google Scholar 

  10. Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A., Kooij, P. P., Oei, H.Y., van Hagen, M., Postema, P. T., de Jong, M., Reubi, J. C., and et al. Somatostatin receptor scintigraphy with [111 In-DTPA-D-Phe 1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med, 20:716–731, 1993.

    Article  CAS  PubMed  Google Scholar 

  11. Krenning, E. P., Bakker, W. H., Breeman, W. A., Koper, J. W., Kooij, P. P., Ausema, L., Lameris, J. S., Reubi, J. C., and Lamberts, S. W. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet, 1: 242–244, 1989.

    CAS  PubMed  Google Scholar 

  12. Krenning, E. P., Bakker, W.H., Kooij, P. P., Breeman, W. A., Oei, H. Y., de Jong, M., Reubi, J. C., Visser, T. J., Bruns, C, Kwekkeboom, D. J., and et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med, 33: 652–658, 1992.

    CAS  PubMed  Google Scholar 

  13. Bakker, W. H., Albert, R., Bruns, C, Breeman, W. A., Hofland, L. J., Marbach, P., Pless, J., Pralet, D., Stolz, B., Koper, J. W., and et al. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci, 49: 1583–1591, 1991.

    CAS  PubMed  Google Scholar 

  14. Andersson, P., Forssell-Aronsson, E., Johanson, V., Wangberg, B., Nilsson, O., Fjalling, M., and Ahlman, H. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. J Nucl Med, 37: 2002–2006, 1996.

    CAS  PubMed  Google Scholar 

  15. De Jong, M., Bernard, B. F., De Bruin, E., Van Gameren, A., Bakker, W. H., Visser, T. J., Macke, H. R., and Krenning, E. P. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun, 19: 283–288, 1998.

    PubMed  Google Scholar 

  16. Hofland, L. J., van Koetsveld, P. M., Waaijers, M., and Lamberts, S. W. Internalisation of isotope-coupled somatostatin analogues. Digestion, 57: 2–6, 1996.

    CAS  PubMed  Google Scholar 

  17. Duncan, J. R., Stephenson, M. T., Wu, H. P., and Anderson, C. J. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res, 57: 659–671, 1997.

    CAS  PubMed  Google Scholar 

  18. Hornick, C. A., Anthony, C. T., Hughey, S., Gebhardt, B. M., Espenan, G. D., and Woltering, E. A. Progressive nuclear translocation of somatostatin analogs. J Nucl Med, 41: 1256–1263, 2000.

    CAS  PubMed  Google Scholar 

  19. Wang, M., Caruano, A. L., Lewis, M. R., Meyer, L. A., VanderWaal, R. P., and Anderson, C. J. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res, 63: 6864–6869, 2003.

    CAS  PubMed  Google Scholar 

  20. Xue, L. Y., Butler, N. J., Makrigiorgos, G. M., Adelstein, S. J., and Kassis, A. I. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci USA, 99: 13765–13770, 2002.

    CAS  PubMed  Google Scholar 

  21. Bernard, B. F., Krenning, E., Breeman, W. A., Visser, T. J., Bakker, W. H., Srinivasan, A., and de Jong, M. Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun, 21: 1079–1085., 2000.

    CAS  PubMed  Google Scholar 

  22. Slooter, G. D., Breeman, W. A., Marquet, R. L., Krenning, E. P., and van Eijck, C. H. Anti-proliferative effect of radiolabelled octreotide in a métastases model in rat liver. Int J Cancer, 81: 767–771, 1999.

    Article  CAS  PubMed  Google Scholar 

  23. De Jong, M., Breeman, W. A., Bernard, H. F., Kooij, P. P., Slooter, G. D., Van Eijck, C. H., Kwekkeboom, D. J., Valkema, R., Macke, H. R., and Krenning, E. P. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med, 43: 356–366, 1999.

    PubMed  Google Scholar 

  24. Valkema, R., De Jong, M., Bakker, W. H., Breeman, W. A., Kooij, P. P., Lugtenburg, P. J., De Jong, F. H., Christiansen, A., Kam, B. L., De Herder, W. W., Stridsberg, M., Lindemans, J., Ensing, G., and Krenning, E. P. Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: the Rotterdam experience. Semin Nucl Med, 32: 110–122., 2002.

    Article  PubMed  Google Scholar 

  25. Fjalling, M., Andersson, P., Forssell-Aronsson, E., Gretarsdottir, J., Johansson, V., Tisell, L. E., Wangberg, B., Nilsson, O., Berg, G., Michanek, A., Lindstedt, G., and Ahlman, H. Systemic radionuclide therapy using indium-111-DTPA-D-Phe 1-octreotide in midgut carcinoid syndrome. J Nucl Med, 37: 1519–1521, 1996.

    CAS  PubMed  Google Scholar 

  26. Anthony, L. B., Woltering, E. A., Espenan, G. D., Cronin, M. D., Maloney, T. J., and McCarthy, K. E. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med, 32: 123–132., 2002.

    PubMed  Google Scholar 

  27. McCarthy, K. E., Woltering, E. A., and Anthony, L. B. In situ radiotherapy with 111 In-pentetreotide. State of the art and perspectives. Q J Nucl Med, 44: 88–95, 2000.

    CAS  PubMed  Google Scholar 

  28. McCarthy, K. E., Woltering, E. A., Espenan, G. D., Cronin, M., Maloney, T. J., and Anthony, L. B. In situ radiotherapy with 111 In-pentetreotide: initial observations and future directions. Cancer J Sci Am, 4: 94–102,1998.

    CAS  PubMed  Google Scholar 

  29. de Jong, M., Breeman, W. A., Bakker, W. H., Kooij, P. P., Bernard, B. F., Hofland, L. J., Visser, T. J., Srinivasan, A., Schmidt, M. A., Erion, J. L., Bugaj, J. E., Macke, H. R., and Krenning, E. P. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res, 58: 437–441, 1998.

    PubMed  Google Scholar 

  30. Reubi, J. G, Schar, J. C, Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., and Macke, H. R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med, 27: 273–282, 2000.

    Article  CAS  PubMed  Google Scholar 

  31. de Jong, M., Breeman, W. A., Bernard, B. F., Bakker, W. H., Schaar, M., van Gameren, A., Bugaj, J. E., Erion, J., Schmidt, M., Srinivasan, A., and Krenning, E. P. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer, 92: 628–633., 2001.

    PubMed  Google Scholar 

  32. Schmitt, A., Bernhardt, P., Nilsson, O., Ahlman, H., Kolby, L., Schmitt, J., and Forssel-Aronsson, E. Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm, 18: 593–599, 2003.

    Article  CAS  PubMed  Google Scholar 

  33. Schmitt, J. S., Wild, D., Ginj, M., Reubi, J. G, Waser, B., De Jong, M., Bernard, H.F., Krenning, E. P., and Maecke, H. R. DOTA-NOC, a high affinity ligand of the somatostatin receptor subtypes 2,3 and 5 for radiotherapy. J Labelled Cpd Radiopharm, 44: s697–s699, 2001.

    Google Scholar 

  34. Wild, D., Schmitt, J. S., Ginj, M., Macke, H. R., Bernard, B. F., Krenning, E., De Jong, M., Wenger, S., and Reubi, J. C. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging, 30: 1338–1347, 2003.

    Article  CAS  PubMed  Google Scholar 

  35. de Jong, M., Rolleman, E. J., Bernard, B. F., Visser, T. J., Bakker, W. H., Breeman, W. A., and Krenning, E. P. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med, 37: 1388–1392, 1996.

    PubMed  Google Scholar 

  36. Bernard, B. F., Krenning, E. P., Breeman, W. A., Rolleman, E. J., Bakker, W. H., Visser, T. J., Macke, H., and de Jong, M. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med, 38: 1929–1933, 1997.

    CAS  PubMed  Google Scholar 

  37. Rolleman, E. J., Valkema, R., deJong, M., Kooij, P. P., and Krenning, E. P. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging, 30: 9–15, 2003.

    Article  CAS  PubMed  Google Scholar 

  38. Bodei, L., Cremonesi, M., Zoboli, S., Grana, C., Bartolomei, M., Rocca, P., Caracciolo, M., Macke, H. R., Chinol, M., and Paganelli, G. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging, 30: 207–216, 2003.

    CAS  PubMed  Google Scholar 

  39. Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P. M., Konijnenberg, M. W., Srinivasan, A., Erion, J. L., Schmidt, M. A., Bugaj, J. E., de Jong, M., and Krenning, E. P. [177Lu-DOTA0,Tyr3]octreotate: comparison with [111ln-DTPA0]octreotide in patients. Eur J Nucl Med, 28: 1319–1325, 2001.

    Article  CAS  PubMed  Google Scholar 

  40. Kwekkeboom, D. J., Kooij, P. P., Bakker, W. H., Macke, H. R., and Krenning, E. P. Comparison of 111 In-DOTA-Tyr3-octreotide and 111 In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med, 40: 762–767., 1999.

    CAS  PubMed  Google Scholar 

  41. de Jong, M., Breeman, W. A., Bernard, B. F., Bakker, W. H., Visser, T. J., Kooij, P. P., van Gameren, A., and Krenning, E. P. Tumor Response After [(90)Y-DOTA(0),Tyr(3)]Octreotide Radionuclide Therapy in a Transplantable Rat Tumor Model Is Dependent on Tumor Size. J Nucl Med, 42: 1841–1846., 2001.

    PubMed  Google Scholar 

  42. Anderson, C. J., Jones, L. A., Bass, L. A., Sherman, E. L., McCarthy, D. W., Cutler, P. D., Lanahan, M. V., Cristel, M. E., Lewis, J. S., and Schwarz, S. W. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J Nucl Med, 39: 1944–1951, 1998.

    CAS  PubMed  Google Scholar 

  43. Lewis, J. S., Lewis, M. R., Cutler, P. D., Srinivasan, A., Schmidt, M. A., Schwarz, S. W., Morris, M. M., Miller, J. P., and Anderson, C. J. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res, 5: 3608–3616, 1999.

    CAS  PubMed  Google Scholar 

  44. Stolz, B., Smith-Jones, P., Albert, R., Tolcsvai, L., Briner, U., Ruser, G., Macke, H., Weckbecker, G., and Bruns, C. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion, 57: 17–21., 1996.

    CAS  PubMed  Google Scholar 

  45. Stolz, B., Weckbecker, G., Smith-Jones, P. M., Albert, R., Raulf, F., and Bruns, C. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhel, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med, 25: 668–674, 1998.

    Article  CAS  PubMed  Google Scholar 

  46. Breeman, W. A., Mearadji, A., Capello, A., Bernard, B. F., van Eijck, C. H., Krenning, E. P., and de Jong, M. Anti-tumor effect and increased survival after treatment with [177Lu-DOTAO,Tyr3]octreotate in a rat liver micrometastases model, Int J Cancer, 104: 376–379, 2003.

    Article  CAS  PubMed  Google Scholar 

  47. Erion, J. L., Bugaj, J. E., Schmidt, M. A., Wilhelm, R. R., and Srinivasan, A. High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-octreotate in a rat tumor model. J Nucl Med, 40: 223p, 1999.

    Google Scholar 

  48. De Jong, M., Bernard, H. F., Breeman, W. A. P., van Gameren, A., and Krenning, E. P. Combination of 90Y-and 177Lu-labeled somatostatin analogs is superior for radionuclide therapy compared to 90Y-or 177Lu-labeled analogs only. J Nucl Med, 43: 123–124P, 2002.

    Google Scholar 

  49. Otte, A., Herrmann, R., Heppeler, A., Behe, M., Jermann, E., Powell, P., Maeckc, H. R., and Muller, J. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med, 26: 1439–1447, 1999.

    Article  CAS  PubMed  Google Scholar 

  50. Otte, A., Herrmann, R., Macke, H. R., and Muller-Brand, J. [Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors]. Schweiz. Rundsch Med Prax, 88: 1263–1268, 1999.

    CAS  PubMed  Google Scholar 

  51. Otte, A., Mueller-Brand, J., Delias, S., Nitzsche, E. U., Herrmann, R., and Maeckc, H. R. Yttrium-90-labelled somatostatin-analogue for cancer treatment [letter]. Lancet, 351: 417–418, 1998.

    Article  CAS  PubMed  Google Scholar 

  52. Waldherr, C., Pless, M., Maecke, H. R., Haldemann, A., and Mueller-Brand, J. The clinical value of [90Y-DOTA]-D-Phel-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol, 12: 941–945., 2001.

    Article  CAS  PubMed  Google Scholar 

  53. Waldherr, C., Pless, M., Maecke, H. R., Schumacher, T., Crazzolara, A., Nitzsche, E. U., Haldemann, A., and Mueller-Brand, J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med, in press, 2002.

    Google Scholar 

  54. Waldherr, C., Schumacher, T., Maecke, H. R., Schirp, U., Forrer, F., Nitzsche, E. U., and Mueller-Brand, J. Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors? Eur J Nucl Med, 29: S100, 2002.

    Google Scholar 

  55. Paganelli, G., Zoboli, S., Cremonesi, M., Bodei, L., Ferrari, M., Grana, C., Bartolomei, M., Orsi, F., De Cicco, C., Macke, H. R., Chinol, M., and de Braud, F. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phel-Tyr3-octreotide. Eur J Nucl Med, 28: 426–434., 2001.

    Article  CAS  PubMed  Google Scholar 

  56. Paganelli, G., Zoboli, S., Cremonesi, M., Macke, H. R., and Chinol, M. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe l-Tyr3-Octreotide: preliminary report in cancer patients. Cancer Biother Radiopharm, 14: 477–483., 1999.

    CAS  PubMed  Google Scholar 

  57. Chinol, M., Bodei, L., Cremonesi, M., and Paganelli, G. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med, 32: 141–147., 2002.

    PubMed  Google Scholar 

  58. Smith, M. C, Liu, J., Chen, T., Schran, H., Yeh, C. M., Jamar, F., Valkema, R., Bakker, W., Kvols, L., Krenning, E., and Pauwels, S. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion, 62: 69–72., 2000.

    Article  CAS  PubMed  Google Scholar 

  59. Valkema, R., Kvols, L., Jamar, F., Bakker, W. H., Smith, C., Krenning, E. P., and Pauwels, S. Phase 1 study of therapy with 90Y-SMT487 (OctreoTher) in patients with somatostatin receptor-positive tumors. J Nucl Med, 43: 33P, 2002.

    Google Scholar 

  60. Jonard, P., Jamar, F., Walrand, S., Collait, J. P., Valkema, R., Bakker, W. H., Labar, D., Smith, C., Kvols, L., Krenning, E. P., and Pauwels, S. Tumor dosimetry based on PET 86Y-DOTA-Tyr3-octreotide (SMT487) and CT-scan predicts tumor response to 90Y-SMT487 (OctreoTher). J Nucl Med, 41: 111P, 2000.

    Google Scholar 

  61. Bushnell, D., O’Dorisio, T., Menda, Y., Carlisle, T., Zehr, P., Connolly, M., Karwal, M., Miller, S., Parker, S., and Bouterfa, H. Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med, 44: 1556–1560, 2003.

    PubMed  Google Scholar 

  62. Bushnell, D., Menda, Y., Madsen, M., O’Dorisio, T., Carlisle, T., Zehr, P., Ponto, L., Karwal, M., Parker, S., Ponto, J., Connolly, M., and Bouterfa, H. Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher in patients with diffuse somatostatin receptor positive liver metastases. Cancer Biother Radiopharm, 18:581–588, 2003.

    Article  CAS  PubMed  Google Scholar 

  63. Schumacher, T., Hofer, S., Eichhorn, K., Wasner, M., Zimmerer, S., Freitag, P., Probst, A., Gratzl, O., Reubi, J. C, Maecke, R., Mueller-Brand, J., and Merlo, A. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging, 29: 486–493., 2002.

    CAS  PubMed  Google Scholar 

  64. Kwekkeboom, D. J., Bakker, W. H., Kam, B. L., Teunissen, J. J., Kooij, P. P., De Herder, W. W., Feelders, R. A., Van Eijck, C. H., De Jong, M., Srinivasan, A., Erion, J. L., and Krenning, E. P. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging, 30: 417–422., 2003.

    CAS  PubMed  Google Scholar 

  65. Virgolini, I., Traub, T., Novotny, C., Leimer, M., Fuger, B., Li, S. R., Patri, P., Pangerl, T., Angelberger, P., Raderer, M., Burggasser, G., Andreae, F., Kurtaran, A., and Dudczak, R. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des, 8: 1781–1807, 2002.

    Article  CAS  PubMed  Google Scholar 

  66. Virgolini, I., Szilvasi, I., Kurtaran, A., Angelberger, P., Raderer, M., Havlik, E., Vorbeck, F., Bischof, C., Leimer, M., Domer, G., Kletter, K., Niederle, B., Scheithauer, W., and Smith-Jones, P. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med, 39: 1928–1936., 1998.

    CAS  PubMed  Google Scholar 

  67. Virgolini, I., Britton, K., Buscombe, J., Moncayo, R., Paganelli, G., and Riva, P. In-and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med, 32: 148–155., 2002.

    Article  PubMed  Google Scholar 

  68. Virgolini, I., Kurtaran, A., Angelberger, P., Raderer, M., Havlik, E., and Smith-Jones, P. “MAURITIUS”: tumour dose in patients with advanced carcinoma. Ital J Gastroenterol Hepatol, 31 Suppl 2: S227–230., 1999.

    PubMed  Google Scholar 

  69. Smith-Jones, P. M., Bischof, C., Leimer, M., Gludovacz, D., Angelberger, P., Pangerl, T., Peck-Radosavljevic, M., Hamilton, G., Kaserer, K., Kofier, A., Schlangbauer-Wadl, H., Traub, T., and Virgolini, I. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology, 140: 5136–5148., 1999.

    Article  CAS  PubMed  Google Scholar 

  70. Froidevaux, S., Heppeler, A., Eberle, A. N., Meier, A. M., Hausler, M., Beglinger, C., Behe, M., Powell, P., and Macke, H. R. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled l,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology, 141: 3304–3312., 2000.

    Article  CAS  PubMed  Google Scholar 

  71. Leimer, M., Kurtaran, A., Smith-Jones, P., Raderer, M., Havlik, E., Angelberger, P., Vorbeck, F., Niederle, B., Herold, C., and Virgolini, I. Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med, 39: 2090–2094., 1998.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands

    Marion de Jong, Roelf Valkema, Dik J Kwekkeboom & Eric P Krenning

Authors
  1. Marion de Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roelf Valkema
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dik J Kwekkeboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eric P Krenning
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, McGill University Heath Center, Montréal, Québec, Canada

    Coimbatore B. Srikant

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science + Business Media, Inc.

About this chapter

Cite this chapter

de Jong, M., Valkema, R., Kwekkeboom, D.J., Krenning, E.P. (2004). Somatostatin Receptor Targeted-Radio-Ablation of Tumors. In: Srikant, C.B. (eds) Somatostatin. Endocrine Updates, vol 24. Springer, Boston, MA. https://doi.org/10.1007/1-4020-8033-6_15

Download citation

  • DOI: https://doi.org/10.1007/1-4020-8033-6_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-7799-9

  • Online ISBN: 978-1-4020-8033-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation